Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pharmacist teamwork boosts pneumonia vaccine rates in hospitals

NCT ID NCT05060146

Prevention Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a structured collaboration between pharmacists and doctors could improve pneumococcal vaccination rates in patients at high risk for infection. Over 600 hospitalized adults with chronic conditions or weakened immune systems took part. The pharmacist reviewed medications, educated patients, and coordinated vaccination after discharge.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pneumococcal vaccine
What this could lead to
If successful, this approach could significantly increase vaccination rates in at-risk patients, reducing serious infections like pneumonia and meningitis.
What could go wrong
This is a completed study, so results are available. However, the intervention relies on multiple steps (pharmacist, doctor, nurse) which may not work in all hospitals or countries.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

646 people

The number who actually took part.

Started

Sep 2022

Finished

Jun 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The patient must have given their free and informed oral consent * The patient must be a member or beneficiary of a health insurance plan * The patient is admitted to full hospitalization in a surgical or medical department. * The patient will benefit from a reconciliation of drug treatments. * The patient is considered at risk of pneumococcal infection according to the recommendations of March 2017 of the High Council of Public Health (HCSP) * Pneumococcal vaccination is not up to date according to the HCSP 2017 recommendations. Exclusion Criteria: * The subject is participating in a category 1 interventional study * The patient has participated in a category 1 trial within the previous 3 months or is in a period of exclusion determined by a previous study * It is impossible to give the subject informed information * The patient is under safeguard of justice or state guardianship * The patient is not in a fit state to express consent * The patient is pregnant, parturient or breast feeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Streptococcus pneumoniae infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Streptococcus pneumoniae infection

Contacts and locations

Locations

  • CH Alès Cévennes

    Alès, France

  • CH Comminges Pyrénées

    Saint-Gaudens, France

  • CH de Bagnols sur Cèze

    Bagnols-sur-Cèze, France

  • CH de Montauban

    Montauban, France

  • CH de Perpignan

    Perpignan, France

  • CH du Bassin de Thau

    Sète, France

  • CHU de Montpellier

    Montpellier, France

  • CHU de Nimes

    Nîmes, France

  • CHU de Toulouse

    Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.